Chimeric Antigen Receptor Natural Killer T-Cell Therapy for Tumors: Promise and Progress

Area of Science:

• Immunology
• Oncology
• Cellular Therapy

Background:

• Chimeric antigen receptor-engineered invariant natural killer T (CAR-NKT) cells represent an innovative cellular immunotherapy.
• CAR-NKT therapy offers potential advantages over conventional CAR-T cell therapy for solid tumor treatment.

Purpose of the Study:

• To review the research progress and current applications of CAR-NKT cells in solid tumors.
• To highlight the potential and challenges of CAR-NKT cell therapy for solid tumors.

Main Methods:

• Review of current studies on CAR-NKT cell recognition, tumor microenvironment infiltration, and anti-tumor mechanisms.
• Comparison of CAR-NKT therapy with CAR-T therapy regarding anti-tumor potency and graft-versus-host disease.
• Analysis of CAR-NKT cells' role in regulating immune cells (dendritic cells, NK cells, CD8+ T cells) and early clinical/preclinical trial data.

Main Results:

• CAR-NKT cells effectively recognize tumor antigens, infiltrate tumors, and exert anti-tumor effects via direct killing and cytokine secretion.
• CAR-NKT therapy demonstrates superior anti-tumor potency and a lower incidence of graft-versus-host disease compared to CAR-T therapy.
• CAR-NKT cells enhance anti-tumor immunity and have shown good safety and preliminary efficacy in early trials for neuroblastoma and other solid tumors.

Conclusions:

• CAR-NKT cell therapy holds significant potential for clinical translation in solid tumors.
• Challenges include antigen selection, in vivo expansion, tumor heterogeneity, and immune suppression.
• Future directions involve cytokine engineering and combination therapies to advance CAR-NKT cell immunotherapy.